Akèy › Sklerodèm
Etid klinik pou Sklerodèm ap rekrite nan Etazini
33 etid pou Sklerodèm ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- New York City, NY11 etid
- Ann Arbor, MI10 etid
- Chicago, IL10 etid
- Houston, TX9 etid
- Boston, MA7 etid
- Durham, NC7 etid
- Los Angeles, CA7 etid
- New Orleans, LA6 etid
- Philadelphia, PA6 etid
- Baltimore, MD6 etid
- Dallas, TX5 etid
- Pittsburgh, PA5 etid
- Plantation, FL4 etid
- Kansas City, KS4 etid
- New Haven, CT4 etid
- Phoenix, AZ4 etid
- Edison, NJ4 etid
- Washington, DC4 etid
- Charleston, SC4 etid
- Miami, FL4 etid
- Minneapolis, MN3 etid
- Charlotte, NC3 etid
- Jacksonville, FL3 etid
- St. Louis, MO3 etid
- San Diego, CA3 etid
- Mountain View, CA3 etid
- Aurora, CO3 etid
- Tucson, AZ3 etid
- Cedar Rapids, IA3 etid
Pa eta
- Alabama3 etid
- Arizona6 etid
- Colorado4 etid
- Connecticut4 etid
- Distrik Columbia4 etid
- Florid9 etid
- Illinois11 etid
- Iowa3 etid
- Kalifòni13 etid
- Kansas5 etid
- Kentucky3 etid
- Lwizyàn6 etid
- Maryland6 etid
- Massachusetts7 etid
- Michigan10 etid
- Minnesota5 etid
- Missouri3 etid
- New Jersey5 etid
- New York11 etid
- North Carolina9 etid
- Ohio4 etid
- Pennsylvania10 etid
- South Carolina4 etid
- Tennessee5 etid
- Texas12 etid
- Virginia3 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07497087A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06655155Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT03816345A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
Ap rekriteFaz 1
Laj 18 a 74 · Tout sèks · Mizajou Sep 10, 2026 · NCT07085104A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT05878717FT839 in Autoimmune Diseases
Ap rekriteFaz 1/2
Laj 18 a 70 · Tout sèks · Mizajou Sep 2, 2026 · NCT07800871A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
Ap rekriteFaz 1
Laj 18 a 70 · Tout sèks · Mizajou Aug 28, 2026 · NCT06925542Platform Clinical Study for Conquering Scleroderma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT06195072RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
Ap rekriteFaz 2/3
Laj 18 a 75 · Tout sèks · Mizajou Aug 17, 2026 · NCT06328777Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
Ap rekriteFaz 2
Laj 8 a 60 · Tout sèks · Mizajou Aug 14, 2026 · NCT03630211A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
Ap rekriteFaz 1/2
Laj 18 a 75 · Tout sèks · Mizajou Aug 7, 2026 · NCT06733935AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 31, 2026 · NCT06991114A Study of AZD0120 in Autoimmune Diseases
Ap rekriteFaz 1
Laj 18 a 75 · Tout sèks · Mizajou Jul 28, 2026 · NCT07295847Diffuse Cutaneous Scleroderma (DSSc) SFDI Study
Ap rekriteVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Jul 23, 2026 · NCT07090226A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 14, 2026 · NCT07115745A Study of Microbiome Transplantation for the Treatment of Constipation and/or Significant Bloating in Patients With Systemic Sclerosis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 8, 2026 · NCT06827977Systemic Sclerosis DIet for GastrointESTinal Symptoms
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Jul 1, 2026 · NCT07402226US Zamto-cel Autoimmune Diseases
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 11, 2026 · NCT06708845A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
Ap rekriteFaz 1
Laj 12 a 70 · Tout sèks · Mizajou May 22, 2026 · NCT06308978Morphea in Adults and Children (MAC) Cohort Study: A Morphea Registry and DNA Repository
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Jiska laj 90 · Tout sèks · Mizajou May 12, 2026 · NCT01808937Intralesional Injection of STS in Treatment of Calcinosis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou May 5, 2026 · NCT06672822Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Apr 15, 2026 · NCT06434363A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Mar 31, 2026 · NCT07047690Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis
Ap rekriteFaz 2
Laj 18 a 80 · Tout sèks · Mizajou Mar 27, 2026 · NCT03844061Open Label Treprostinil Raynaud's Study
Ap rekriteFaz 4
Laj 18 ak plis · Tout sèks · Mizajou Mar 24, 2026 · NCT07112183Sous ClinicalTrials.gov, done yo ranmase Oct 3, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.